Exploring Skin Adverse Events and Mechanisms of Apalutamide Using Data Mining Algorithms and Network Pharmacology

Overview

Journal Front Pharmacol

Date 2025 Feb 28

PMID 40017595

Authors

Yaqing Chen

Longzhuan Huang

Wenwei Li

Hangye Gu

Yong Chen

Affiliations

Soon will be listed here.

Abstract

Background: Skin adverse events of apalutamide pose a major challenge to its clinical use, particularly the severe and difficult to identify toxic epidermal necrolysis. For the purpose of providing the basis for the clinical monitoring of the administration of apalutamide and further research. This study examined the pathways of apalutamide and Stephen Johnson Syndrome/Toxic Epidermal Necrolysis using network pharmacology and data mining tools to analyze skin adverse events.

Methods: Using the Information Component method and the Reporting Odds Ratio, the relationship between apalutamide and skin adverse events was evaluated. Molecular docking was utilized to explore the potential mechanism of apalutamide and Stephen Johnson Syndrome/toxic epidermal necrolysis.

Results: With a median time to onset of all skin adverse events of 55 days, a total of 21 skin-related adverse events were found. Low body weight and advanced age may be major hazards for skin adverse events with apalutamide. The results showed a substantial association between apalutamide and Stephen Johnson Syndrome/toxic epidermal necrolysis, and the mechanism behind this association may be the binding of apalutamide to JAK1 and JAK2.

Conclusion: Special attention is recommended for skin adverse events when using apalutamide, especially for rapidly progressing and severe adverse events. To confirm the connection between the triad of Janus kinase, apalutamide, and skin adverse events, further research is required in the future.

References

Pan A, Reingold R, Zhao J, Moy A, Kraehenbuehl L, Dranitsaris G . Dermatological Adverse Events in Prostate Cancer Patients Treated with the Androgen Receptor Inhibitor Apalutamide. J Urol. 2022; 207(5):1010-1019. PMC: 9554897. DOI: 10.1097/JU.0000000000002425. View

Sherman B, Hao M, Qiu J, Jiao X, Baseler M, Lane H . DAVID: a web server for functional enrichment analysis and functional annotation of gene lists (2021 update). Nucleic Acids Res. 2022; 50(W1):W216-W221. PMC: 9252805. DOI: 10.1093/nar/gkac194. View

Kim S, Chen J, Cheng T, Gindulyte A, He J, He S . PubChem 2023 update. Nucleic Acids Res. 2022; 51(D1):D1373-D1380. PMC: 9825602. DOI: 10.1093/nar/gkac956. View

Stern R, Divito S . Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis: Associations, Outcomes, and Pathobiology-Thirty Years of Progress but Still Much to Be Done. J Invest Dermatol. 2017; 137(5):1004-1008. PMC: 5567821. DOI: 10.1016/j.jid.2017.01.003. View

Berman H, Westbrook J, Feng Z, Gilliland G, Bhat T, Weissig H . The Protein Data Bank. Nucleic Acids Res. 1999; 28(1):235-42. PMC: 102472. DOI: 10.1093/nar/28.1.235. View

Dika E, Patrizi A, Ribero S, Fanti P, Starace M, Melotti B . Hair and nail adverse events during treatment with targeted therapies for metastatic melanoma. Eur J Dermatol. 2016; 26(3):232-9. DOI: 10.1684/ejd.2016.2747. View

Kaffenberger B, Rosenbach M . Toxic epidermal necrolysis and early transfer to a regional burn unit: is it time to reevaluate what we teach?. J Am Acad Dermatol. 2014; 71(1):195-6. DOI: 10.1016/j.jaad.2013.12.048. View

Huang L, Guo T, Zalkikar J, Tiwari R . A Review of Statistical Methods for Safety Surveillance. Ther Innov Regul Sci. 2018; 48(1):98-108. DOI: 10.1177/2168479013514236. View

Ogiji E, Aboheimed N, Ross K, Voller C, Siner R, Jensen R . Greater mechanistic understanding of the cutaneous pathogenesis of Stevens-Johnson syndrome/toxic epidermal necrolysis can shed light on novel therapeutic strategies: a comprehensive review. Curr Opin Allergy Clin Immunol. 2024; 24(4):218-227. PMC: 11213502. DOI: 10.1097/ACI.0000000000000993. View

10.

Caster O, Aoki Y, Gattepaille L, Grundmark B . Disproportionality Analysis for Pharmacovigilance Signal Detection in Small Databases or Subsets: Recommendations for Limiting False-Positive Associations. Drug Saf. 2020; 43(5):479-487. PMC: 7165139. DOI: 10.1007/s40264-020-00911-w. View

11.

Suzuki H, Okihara K, Miyake H, Fujisawa M, Miyoshi S, Matsumoto T . Alternative nonsteroidal antiandrogen therapy for advanced prostate cancer that relapsed after initial maximum androgen blockade. J Urol. 2008; 180(3):921-7. DOI: 10.1016/j.juro.2008.05.045. View

12.

Kim T, Lee Y, Koo K . Current Status and Future Perspectives of Androgen Receptor Inhibition Therapy for Prostate Cancer: A Comprehensive Review. Biomolecules. 2021; 11(4). PMC: 8064397. DOI: 10.3390/biom11040492. View

13.

Bastuji-Garin S, Fouchard N, Bertocchi M, Roujeau J, Revuz J, Wolkenstein P . SCORTEN: a severity-of-illness score for toxic epidermal necrolysis. J Invest Dermatol. 2000; 115(2):149-53. DOI: 10.1046/j.1523-1747.2000.00061.x. View

14.

Yuan J, Lu H, Zuo X, Yin L, Pu Y, Zhang J . Adverse Event Assessment of Upadacitinib: A Pharmacovigilance Study Based on the FAERS Database. Pharmacoepidemiol Drug Saf. 2024; 33(10):e70030. DOI: 10.1002/pds.70030. View

15.

Stelzer G, Rosen N, Plaschkes I, Zimmerman S, Twik M, Fishilevich S . The GeneCards Suite: From Gene Data Mining to Disease Genome Sequence Analyses. Curr Protoc Bioinformatics. 2016; 54:1.30.1-1.30.33. DOI: 10.1002/cpbi.5. View

16.

Huang M, Armstrong A . Janus-kinase inhibitors in dermatology: A review of their use in psoriasis, vitiligo, systemic lupus erythematosus, hidradenitis suppurativa, dermatomyositis, lichen planus, lichen planopilaris, sarcoidosis and graft-versus-host disease. Indian J Dermatol Venereol Leprol. 2023; 90(1):30-40. DOI: 10.25259/IJDVL_15_2023. View

17.

Gibson A, Ram R, Gangula R, Li Y, Mukherjee E, Palubinsky A . Multiomic single-cell sequencing defines tissue-specific responses in Stevens-Johnson syndrome and toxic epidermal necrolysis. Nat Commun. 2024; 15(1):8722. PMC: 11461852. DOI: 10.1038/s41467-024-52990-3. View

18.

Rajaram P, Rivera A, Muthima K, Olveda N, Muchalski H, Chen Q . Second-Generation Androgen Receptor Antagonists as Hormonal Therapeutics for Three Forms of Prostate Cancer. Molecules. 2020; 25(10). PMC: 7287767. DOI: 10.3390/molecules25102448. View

19.

Omlin A, Sartor O, Rothermundt C, Cathomas R, de Bono J, Shen L . Analysis of Side Effect Profile of Alopecia, Nail Changes, Peripheral Neuropathy, and Dysgeusia in Prostate Cancer Patients Treated With Docetaxel and Cabazitaxel. Clin Genitourin Cancer. 2015; 13(4):e205-e208. DOI: 10.1016/j.clgc.2015.01.010. View

20.

Knox C, Wilson M, Klinger C, Franklin M, Oler E, Wilson A . DrugBank 6.0: the DrugBank Knowledgebase for 2024. Nucleic Acids Res. 2023; 52(D1):D1265-D1275. PMC: 10767804. DOI: 10.1093/nar/gkad976. View